Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
NeuroMetrix, Inc. (NURO)
|
Add to portfolio |
|
|
|
| Price: |
$3.72
| | Metrics |
| OS: |
8.58
|
M
| |
|
|
| Market cap: |
$31.9
|
M
| |
|
|
|
Net cash:
|
$2.86
|
M
| |
$0.33
|
per share
|
|
EV:
|
$29.1
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 8.3 | 8.3 | 7.4 | 9.3 | 16.1 | 17.1 | 12.0 | 7.3 |
| Revenue growth | 0.0% | 11.9% | -20.4% | -42.4% | -5.9% | 42.1% | 64.8% | 32.4% |
| Cost of goods sold | 2.5 | 2.3 | 2.1 | 7.0 | 8.7 | 10.2 | 7.1 | 4.0 |
| Gross profit | 5.8 | 5.9 | 5.2 | 2.2 | 7.4 | 6.9 | 4.9 | 3.3 |
| Gross margin | 69.6% | 71.7% | 71.2% | 24.2% | 45.9% | 40.1% | 40.9% | 45.9% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 2.9 | 1.6 | 1.4 | 4.8 | 9.7 | 10.8 | 10.9 | 7.2 |
| Research and development | 3.2 | 2.6 | 2.4 | 3.1 | 5.1 | 3.5 | 4.4 | 3.9 |
| General and administrative | 4.4 | 4.0 | 3.5 | 5.9 | 4.8 | 5.7 | 4.9 | 5.5 |
| EBIT | -4.7 | -2.3 | -2.1 | -11.5 | -12.3 | -13.1 | -15.2 | -13.3 |
| EBIT margin | -57.4% | -27.7% | -28.4% | -124.4% | -76.4% | -76.5% | -126.4% | -181.9% |
| Pre-tax income | -4.4 | -2.3 | -2.1 | -3.8 | 0.0 | -12.9 | -14.9 | -9.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -4.4 | -2.3 | -2.1 | -3.8 | 0.0 | -19.7 | -34.8 | -21.1 |
| Net margin | -53.5% | -27.6% | -28.4% | -40.7% | 0.1% | -115.5% | -289.0% | -288.6% |
| |
| Diluted EPS | ($0.62) | ($0.45) | ($0.69) | ($3.90) | $0.02 | ($11.60) | ($58.21) | ($7.75) |
| Shares outstanding (diluted) | 7.1 | 5.1 | 3.0 | 1.0 | 1.4 | 1.7 | 0.6 | 2.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|